Conformity Decisions Based on Measurement Uncertainty—a Case Study Applied to Agar Diffusion Microbiological Assay
- 17 Downloads
Antimicrobial activity of drug products containing antibiotics is often measured using microbiological assays. However, the high values of measurement uncertainty associated with the analytical results obtained from microbiological assays may be an issue to conformity decisions.
The aim of this work was to estimate the risk of false decisions in conformity assessment due to measurement uncertainty for the potency of apramycin in pharmaceutical drug products. Monte Carlo method (MCM) simulations were performed in order to estimate global consumers’ (Rc) and producers’ (Rp) risks using a Bayesian approach and specific consumers’ (R′c) and producers’ (R′p) risks using a frequentist approach.
Despite of the high value of measurement uncertainty, Rc and Rp were found to be 0.0% and 0.3%, respectively. However, R′c and R′p were found to be high when the analytical result is close to the specification limits. Risk estimation using Bayesian approach is recommended to be applied by manufacturers, while frequentist approach may be an alternative to regulatory and third-party laboratories.
KeywordsMeasurement uncertainty Conformity assessment Risk of false decisions Microbiological assay Monte Carlo method (MCM)
This study was funded by FAPESP - Fundação de Amparo à Pesquisa do Estado de São Paulo (2016/04100-8 and 2017/04539-2) and CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.T. J. A. Pinto, T. M. Kaneko, A. F. Pinto, Controle biológico de qualidade de produtos farmacêuticos, correlatos, cosméticos, 4ª ed., São Paulo: Manole. 2014.Google Scholar
- 2.Agência Nacional de Vigilância Sanitária (ANVISA). Farmacopéia Brasileira 5ª Edição. In: Brasília; 2010.Google Scholar
- 3.United States Pharmacopeial Convention, “<81> Antibiotics - Microbial tests,” em United States Pharmacopeia (USP 40), Rockville. 2017.Google Scholar
- 4.Lazo JS, Bruton LL, Parker KL. As bases farmacológicas da terapêutica. Rio de Janeiro, RJ: McGraw-Hill; 2006.Google Scholar
- 9.Lourenço FR, Barbosa EA, Pinto TA. Microbiological assay for apramycin soluble powder. Lat Am J Pharm. 2011;30(3):554–7.Google Scholar
- 17.A. Ribeiro, M. Gölze, EUROLAB technical report 1/2017 "Decision rules applied to conformity assessment", 2017.Google Scholar
- 18.S.R.R. Ellison, A. Williams (Eds.), EURACHEM/CITAC guide: use of uncertainty information in compliance assessment, 2017.Google Scholar
- 23.Lourenço FR. Uncertainty measurement of microbiological assay for apramycin soluble powder. Lat Am J Pharm. 2013;32(5):640–5.Google Scholar
- 24.Ellison SLR, Williams A, editors. Eurachem/CITAC guide: Quantifying uncertainty in analytical measurement. Rome: EURACHEM/CITAC; 2012.Google Scholar
- 25.Lourenço FR, Kaneko TM, Pinto TA. Evaluating measurement uncertainty in the microbiological assay of vancomycin from methodology validation data. J AOAC Int. 2007;90(5):1383–6.Google Scholar
- 26.Bettencourt da Silva R, Williams A. Eurachem/CITAC guide: setting and using target uncertainty in chemical measurement. 2015.Google Scholar
- 28.International Organizatio for Standardization, ISO/IEC 17025:2017 - General requirements for the competence of testing and calibration laboratories. 2017.Google Scholar
- 30.S. N. Politis, P. Colombo, G. Colombo, D. M. Rekkas, Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm, vol. 43, n° 6, pp. 889–901, 2017.Google Scholar
- 31.Fukuda IM, Pinto CFF, Moreira C d S, Saviano AM, Lourenço FR. Design of Experiments (DoE) applied to pharmaceutical and analytical Quality by Design (QbD). Braz J Pharm Sci. 2018;54(Special):63–78.Google Scholar